The global LV ECVF demonstrated significant relationships with LVEF (r = − 0.51, P = 0.006), peak VO2 (r = − 0.42, P = 0.032), cancer type (higher in lung or other chest malignancy vs. breast cancer; P = 0.020) and use of angiotensin blockade (lower in patients on ACE-I/ARB; P = 0.007) (Supplemental Fig. 1). The gene discussed is ACE; the disease is breast cancer.